Literature DB >> 33989413

People With Hematological Malignancies Treated With Bone Marrow Transplantation Have Improved Function, Quality of Life and Fatigue Following Exercise Intervention: A Systematic Review and Meta-Analysis.

Shaza Abo1, Linda Denehy2, David Ritchie3, Kuan-Yin Lin4, Lara Edbrooke5, Cassie McDonald6, Catherine L Granger6.   

Abstract

OBJECTIVE: For people with hematological malignancies treated with bone marrow transplantation (BMT), this systematic review aimed to identify, evaluate, and synthesize the evidence examining the effect of exercise training on the outcomes of exercise capacity, health-related quality of life (HRQoL), and hospital length of stay and to identify any difference in the effect on people treated with allogeneic versus autologous transplantation.
METHODS: Five electronic databases were systematically searched from inception to December 5, 2020. Prospective studies with a comparator group, with or without randomization, were included if they investigated the effects of an exercise intervention compared with usual care or another intervention in adults who had a hematological malignancy and were undergoing BMT. Primary outcomes of interest were functional exercise capacity and HRQoL; secondary outcomes included strength, fatigue, hospital length of stay, and feasibility. Only randomized controlled trials were included in the meta-analyses. Risk of bias was evaluated using the Physiotherapy Evidence Database or Newcastle-Ottawa Scale; quality of evidence for meta-analyses was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach.
RESULTS: Twenty-four randomized controlled trials and 3 prospective nonrandomized experimental trials were included (n = 2432). There was moderate-quality evidence that exercise improves functional exercise capacity (mean difference [MD] = 29 m; 95% CI = 12.59 to 45.4), global HRQoL (MD = 3.38 points; 95% CI = 0.37 to 6.39), and fatigue (MD = 2.52 points; 95% CI = 0.42 to 4.63) and low-quality evidence for reduced hospital length of stay (MD = 2.07 days; 95% CI = 0.43 to 3.72). These effects were more pronounced in recipients of allogeneic transplantation. No serious adverse events were associated directly with exercise in the included studies.
CONCLUSIONS: Exercise is safe and improves outcomes, including functional exercise capacity, HRQoL, and hospital length of stay, in adults undergoing BMT. IMPACT: The results of this systematic review support the implementation of exercise programs in adults undergoing BMT, particularly recipients of allogeneic transplantation.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Physical Therapy Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Bone Marrow Transplantation; Exercise; Hematological Malignancies; Quality of Life; Stem Cell Transplantation

Year:  2021        PMID: 33989413     DOI: 10.1093/ptj/pzab130

Source DB:  PubMed          Journal:  Phys Ther        ISSN: 0031-9023


  3 in total

1.  Quality of life of patients with hematological malignancies and factors affecting health state utility values.

Authors:  Keiichi Osaki; Shinichiro Morishita; Suzuho Takami; Yuki Sakai; Akiho Kamimura; Atsushi Shindo; Eri Kawata
Journal:  Support Care Cancer       Date:  2022-03-12       Impact factor: 3.603

2.  Exercise in allogeneic bone marrow transplantation: a qualitative representation of the patient perspective.

Authors:  Shaza Abo; Selina M Parry; David Ritchie; Gabriella Sgro; Dominic Truong; Linda Denehy; Catherine L Granger
Journal:  Support Care Cancer       Date:  2022-03-16       Impact factor: 3.359

3.  Impact of SARS-CoV-2 pandemic on rehabilitation of patients after high-dose chemotherapy with allogeneic hematopoietic stem cell transplantation: results of a monocentric, retrospective analysis.

Authors:  Thomas Kiefer; Christian Lüders; Heinz Völler; Georg Daeschlein
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-14       Impact factor: 4.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.